直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Redemption of Loyalty Points Is a Patent-Ineligible Abstract Idea, Federal Circuit Holds

February 26, 2021

Authored and Edited by Zan Newkirk; Brooke M Wilner; Amanda K. Murphy, Ph.D.

In cxLoyalty, Inc. v. Maritz Holdings Inc., Nos. 2020-1307, 1309 (February 8, 2021), the Federal Circuit found both original and substitute claims in a covered business method review ineligible for patent protection under 35 U.S.C. § 101.

cxLoyalty filed a petition for covered business method review, challenging claims 1–15 of U.S. Patent No. 7,134,087, owned by Maritz. The ’087 patent claimed a system and method that automates the process of redeeming credit card loyalty points for rewards. Instead of requiring human participation, as in traditional systems, the ’087’s system uses computer-based interfaces to streamline the process.

The Board found all challenged claims were patent ineligible because they related to an abstract idea under 35 U.S.C. § 101. But the Board found no such issue with Maritz’s substitute claims, 16–23, deeming them patent-eligible. cxLoyalty appealed the Board’s ruling on the substitute claims; Maritz cross-appealed the Board’s ruling on the original claims and the Board’s institution of CBM review.

The Federal Circuit began its analysis by noting that under 35 U.S.C. § 324(e), it does not have authority to rule on Maritz’s challenge to the institution of CBM review. SIPCO, LLC v. Emerson Electric Co., 980 F.3d 865 (Fed. Cir. 2020).

The Court then analyzed whether the original and substitute claims satisfied the requirements of § 101.  The Court began by noting that patent protection is not available for claims directed to an abstract idea. Alice Corp. v. CLS Bank International, 573 U.S. 208, 217. But those claims may still be eligible if they include an “inventive concept” that “transforms the nature of the claim.” Id.

Applying § 101, the Court identified the transactions in the original claims of the ’087 patent as customary. The claimed system, the court held, related to a longstanding commercial practice and amounted to a mere abstract idea. Further, the court held that the claims lacked an “inventive concept,” because the claims simply applied the abstract idea on a computer, replacing traditional human intervention with well-understood and conventional technology.  The Court thus affirmed the Board’s determination that the original claims did not meet the § 101 requirements.

Finding that the substitute claims related to the same abstract idea—and similarly lacked an “inventive concept”—the Court reversed the Board’s ruling on claims 16–23.  On appeal, Maritz argued that the substitute claims recite a novel combination of technical elements that amount to an unconventional technological solution to the problem addressed by the claims, rendering them subject matter eligible. But the Court disagreed, noting that “a patent claim is not eligible under § 101 merely because it recites novel subject matter.” Thus, the Court concluded that neither the original nor substitute claims were patent-eligible.

Tags

United States Court of Appeals for the Federal Circuit (CAFC), Patent Trial and Appeal Board (PTAB), 35 U.S.C. § 101, patent-eligible

Related Practices

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

Related Industries

AI, Electronics, and Information Technology

Electrical and Computer Technology

Related Offices

Atlanta, GA

Washington, DC

Contacts

Zan Newkirk
Associate
Washington, DC
+1 202 408 4107
Email
Amanda K. Murphy, Ph.D.
Partner
London
+44 (0)20 7864 2814
Email

Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Reception

12th Annual Georgia Asian Pacific American Bar Association Gala

May 21, 2026

Atlanta

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Virtual Seminar

Patent "Basics" Seminar

May 19, 2026

Virtual

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP